Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7765313 | 0.76 | LMNA (0.36) | LMNAPOLB | |
| SCHEMBL26934774 | 0.76 | LMNA (0.31) | PLA2G7LMNA | |
| SCHEMBL1363456 | 0.74 | LMNA (0.34) | LMNA | |
| SCHEMBL16683834 | 0.74 | AR (0.35) | PLA2G7LMNAAR | |
| SCHEMBL7021223 | 0.74 | PLA2G7 (0.37) | PLA2G7LMNAHSD17B10AR | |
| SCHEMBL25488449 | 0.74 | PLA2G7 (0.37) | PLA2G7LMNAHSD17B10AR | |
| SCHEMBL19014728 | 0.74 | PLA2G7 (0.37) | PLA2G7LMNAHSD17B10AR | |
| SCHEMBL7058181 | 0.74 | LMNA (0.34) | LMNA | |
| SCHEMBL16702762 | 0.74 | PLA2G7 (0.37) | PLA2G7LMNAHSD17B10AR | |
| SCHEMBL6563168 | 0.74 | PLA2G7 (0.37) | PLA2G7LMNAHSD17B10AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 384 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3931288-B1 | LUBRICATING COMPOSITION FOR PREVENTING OR REDUCING PRE-IGNITION IN AN ENGINE | TOTALENERGIES ONETECH (FR) | 2023-12-20 | — | — | EP | claimed |
| CN-115364692-B | Air filtration composite membrane prepared based on cellulose nanofiber reinforced hydrogel conversion and preparation method thereof | 中国科学院上海高等研究院 | 2023-08-25 | — | — | CN | claimed |
| CN-115364692-A | Air filtration composite membrane prepared based on cellulose nanofiber reinforced hydrogel conversion and preparation method thereof | 中国科学院上海高等研究院 | 2022-11-22 | — | — | CN | claimed |
| WO-2022119431-A1 | PHARMACEUTICAL COMPOSITION HAVING AN ANALGAESIC AND AN ANTIHISTAMINE FOR TREATING RESPIRATORY DISEASES | LABORATORIOS SILANES S.A. DE C.V. (MX) | 2022-06-09 | — | — | WO | claimed |
| CN-113474441-A | Lubricating composition for preventing or reducing pre-ignition in an engine | 道达尔销售服务公司 | 2021-10-01 | — | — | CN | claimed |
| US-10899718-B2 | Polymers functionalized with N-protected hydantoin compounds | BRIDGESTONE CORPORATION (JP) | 2021-01-26 | — | — | US | claimed |
| US-10292967-B2 | Compositions comprising corneoscleral tissue cross-linking agents | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2019-05-21 | — | — | US | claimed |
| EP-3378313-A1 | COMPOSITIONS CONTAINING POLYMERIC, IONIC COMPOUNDS COMPRISING IMIDAZOLIUM GROUPS | BASF SE (DE) | 2018-09-26 | — | — | EP | claimed |
| US-10016354-B2 | Compositions containing polymeric, ionic compounds comprising imidazolium groups | BASF SE (DE) | 2018-07-10 | — | — | US | claimed |
| US-20180065935-A1 | POLYMERS FUNCTIONALIZED WITH N-PROTECTED HYDANTOIN COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2018-03-08 | — | — | US | claimed |
| US-6103739-A | BONE RESORPTION; ANTIINFLAMMATORY AGENTS, SKIN DISORDERS; ANTITUMOR-CARCINOGENIC AND METASTASES AGENTS; ANGIOGENESIS INHIBITORS; ANTIARRITHIC AGENTS; RHEUMATOID DISEASES; OSTEOARTHRITIS, PERIODONTITIS, GINGIVITIS AND CORNEAL ULCERS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-08-15 | — | — | US | claimed |
| EP-0944597-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-09-29 | — | — | EP | claimed |
| EP-0865339-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1998-09-23 | — | — | EP | claimed |
| WO-1998023588-A9 | METALLOPROTEINASE INHIBITORS | — | 1998-09-17 | — | — | WO | claimed |
| WO-1998023588-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1998-06-04 | — | — | WO | claimed |
| WO-1997003783-A9 | METALLOPROTEINASE INHIBITORS | — | 1997-04-03 | — | — | WO | claimed |
| WO-1997003783-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1997-02-06 | — | — | WO | claimed |
| US-5480633-A | LOW LEVELS OF NONIONIC SURFACTANT AND ORGANIC ACID IN WATER; SOAP AND SURFACTANT RESIDUE REMOVAL; SENSITIVITY; LIQUID OR GEL | COLGATE-PALMOLIVE COMPANY (US) | 1996-01-02 | — | — | US | claimed |
| EP-0359803-A1 | PROCESS FOR STABILIZING PHOTOGRAPHIC ELEMENTS. | EASTMAN KODAK CO (US) | 1990-03-28 | — | — | EP | claimed |
| WO-1989008870-A1 | PROCESS FOR STABILIZING PHOTOGRAPHIC ELEMENTS | EASTMAN KODAK COMPANY (US) | 1989-09-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10292967-B2 | Compositions comprising corneoscleral tissue cross-linking agents | SMCHD1, ALDH1A2, CRYAB | PLA2G7 1288/4885LMNA 2353/4885HSD17B10 644/4885 |
| US-20180065935-A1 | POLYMERS FUNCTIONALIZED WITH N-PROTECTED HYDANTOIN COMPOUNDS | PARG, HNMT, PARN | PLA2G7 2819/4885LMNA 336/4885HSD17B10 2953/4885 |
| US-10016354-B2 | Compositions containing polymeric, ionic compounds comprising imidazolium groups | PUF60, POLR1C, PICALM | PLA2G7 4224/4885LMNA 2122/4885HSD17B10 3533/4885 |
| US-10899718-B2 | Polymers functionalized with N-protected hydantoin compounds | HNMT, PARG, PAM | PLA2G7 2655/4885LMNA 455/4885HSD17B10 2835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.